Search Results - Mark Sulkowski

Refine Results
  1. 1
    Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors

    Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors by Mark Sulkowski

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Viral hepatitis and HIV coinfection

    Viral hepatitis and HIV coinfection by Mark Sulkowski

    Published 2007
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Management of Hepatic Complications in HIV‐Infected Persons

    Management of Hepatic Complications in HIV‐Infected Persons by Mark Sulkowski

    Published 2008
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection

    Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection by Mark Sulkowski

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Therapeutic issues in HIV/HCV‐coinfected patients

    Therapeutic issues in HIV/HCV‐coinfected patients by Mark Sulkowski, Y. Benhamou

    Published 2006
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals

    Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals by Susanna Naggie, Mark Sulkowski

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.

    Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1. by David Wyles, Mark Sulkowski, Douglas T. Dieterich

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

    Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals by Liesl M. Hagan, Mark Sulkowski, Raymond F. Schinazi

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

    Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States by Sylvie Deuffic‐Burban, Thierry Poynard, Mark Sulkowski, John B. Wong

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection

    Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection by Mark Sulkowski, Ronald Wasserman, Linda Brooks, Lisa Ball, Robert G. Gish

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus

    Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus by Mark Sulkowski, Eric E. Mast, Leonard B. Seeff, David L. Thomas

    Published 2000
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era

    Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era by Oluwaseun Falade‐Nwulia, Mark Sulkowski, Alana Merkow, Carl A. Latkin, Shruti H. Mehta

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

    Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection by Sammy Saab, Stuart C. Gordon, H. Park, Mark Sulkowski, Aijaz Ahmed, Zobair M. Younossi

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

    Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir by Mark Sulkowski, Shruti H. Mehta, Richard E. Chaisson, David L. Thomas, Richard D. Moore

    Published 2004
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons

    The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons by Shruti H. Mehta, Richard D. Moore, David L. Thomas, Richard E. Chaisson, Mark Sulkowski

    Published 2003
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users

    A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug... by Shruti H. Mehta, David L. Thomas, Mark Sulkowski, Mahboobeh Safaein, David Vlahov, Steffanie A. Strathdee

    Published 2005
    Get full text
    Revisão
    Save to List
    Saved in:
  17. 17
    Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes

    Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes by Zobair M. Younossi, Maria Stepanova, Mark Sulkowski, Susanna Naggie, Massimo Puoti, Chloe Orkin, Sharon Hunt

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection

    Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection by Jordan J. Feld, Ira M. Jacobson, Mark Sulkowski, Fred Poordad, Fernando Tatsch, Jean‐Michel Pawlotsky

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  19. 19
    Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection

    Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection by Oluwaseun Falade‐Nwulia, Catalina Suarez‐Cuervo, David R. Nelson, Michael Fried, Jodi B Segal, Mark Sulkowski

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review

    Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review by Oluwaseun Falade‐Nwulia, Catalina Suarez‐Cuervo, David R. Nelson, Michael Fried, Jodi B Segal, Mark Sulkowski

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: